(0.70%) 5 163.76 points
(0.33%) 38 803 points
(0.80%) 16 286 points
(0.06%) $78.16
(3.55%) $2.22
(1.09%) $2 333.70
(3.60%) $27.65
(0.05%) $965.75
(-0.07%) $0.928
(-0.43%) $10.83
(-0.15%) $0.796
(-0.84%) $90.68
2 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 4.64%
Live Chart Being Loaded With Signals
Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotions, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches...
Stats | |
---|---|
今日成交量 | 576 113 |
平均成交量 | 677 784 |
市值 | 11.82B |
EPS | INR0 ( 2024-01-22 ) |
下一个收益日期 | ( INR0 ) 2024-05-08 |
Last Dividend | INR0.500 ( 2023-07-12 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 13.61 |
ATR14 | INR0.129 (0.11%) |
音量 相关性
Bliss GVS Pharma Limited 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Bliss GVS Pharma Limited 相关性 - 货币/商品
Bliss GVS Pharma Limited 财务报表
Annual | 2022 |
营收: | INR7.52B |
毛利润: | INR3.50B (46.60 %) |
EPS: | INR6.83 |
FY | 2022 |
营收: | INR7.52B |
毛利润: | INR3.50B (46.60 %) |
EPS: | INR6.83 |
FY | 2022 |
营收: | INR7.38B |
毛利润: | INR3.47B (47.02 %) |
EPS: | INR2.24 |
FY | 2021 |
营收: | INR5.69B |
毛利润: | INR2.40B (42.16 %) |
EPS: | INR6.64 |
Financial Reports:
No articles found.
Bliss GVS Pharma Limited Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0.500 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR0.300 | 2010-11-25 |
Last Dividend | INR0.500 | 2023-07-12 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 19 | -- |
Total Paid Out | INR9.35 | -- |
Avg. Dividend % Per Year | 0.46% | -- |
Score | 2.16 | -- |
Div. Sustainability Score | 4.34 | |
Div.Growth Potential Score | 4.25 | |
Div. Directional Score | 4.30 | -- |
Year | Amount | Yield |
---|---|---|
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR1.000 | 0.48% |
2019 | INR1.000 | 0.61% |
2020 | INR0.500 | 0.34% |
2021 | INR1.000 | 0.49% |
2022 | INR1.000 | 0.96% |
2023 | INR0.500 | 0.69% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
RBLBANK.NS | Dividend Junior | 2023-08-18 | Sporadic | 8 | 0.25% | |
KOVAI.NS | Dividend Junior | 2023-08-10 | Annually | 4 | 0.17% | |
EXIDEIND.NS | Dividend Junior | 2023-08-01 | Annually | 22 | 0.76% | |
AMIORG.NS | Dividend Junior | 2023-09-18 | Annually | 3 | 0.15% | |
TALBROAUTO.NS | Dividend Junior | 2023-09-15 | Annually | 18 | 0.48% | |
NGIL.NS | No Dividend Player | 2023-09-21 | Annually | 4 | 0.08% | |
IGPL.NS | Dividend Junior | 2023-08-17 | Sporadic | 18 | 1.12% | |
CHEMFAB.NS | Dividend Junior | 2023-08-22 | Sporadic | 7 | 0.32% | |
SAKSOFT.NS | Dividend Junior | 2023-08-07 | Semi-Annually | 20 | 0.56% | |
LUMAXIND.NS | Dividend Junior | 2023-08-10 | Annually | 23 | 1.26% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.116 | 1.500 | 7.68 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.129 | 1.500 | 9.68 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 12.33 | 1.000 | 6.54 | 6.54 | [3 - 30] |
operatingCashFlowPerShareTTM | 2.70 | 2.00 | 9.10 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.70 | 2.00 | 8.65 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.477 | 1.000 | 5.38 | 5.38 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.165 | 1.000 | 8.69 | 8.69 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 4.34 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 13.65 | 1.000 | 8.72 | 0 | [1 - 100] |
returnOnEquityTTM | 0.129 | 2.50 | 9.79 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.70 | 2.00 | 9.10 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.436 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 2.70 | 2.00 | 9.10 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0371 | 1.500 | -3.09 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0373 | 1.000 | -1.566 | 0 | [0.1 - 0.5] |
Total Score | 4.25 |
Bliss GVS Pharma Limited
Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotions, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. The company also provides other healthcare products, such as balms, creams, lotions, lozenges, nasal inhalers, over the counter products, petroleum jellies, powders, roll-ons, shampoos, soaps, solutions, sprays, syrups, and vaginal washes. In addition, it offers therapeutic products consisting of anti-bacterial, anti-dandruff shampoo, amino acid preparation, iron tonic, antitussive, appetite stimulant, anti-allergic, body supplement, anti-biotic, anti-diabetic, anti-diarrheal, anti-emetic, anti-fungal, anti-haemorrhoidal, anti-helmintic, anti-infective, anti-inflammatory, anti-malarial, anti-microbial, anti-migraine, anti-oxidant, anti-protozoal, ear wax solvent, anti-pyretic, anti-septic, anti-spasmodic, anti-ulcer, and anti-ulcerant; and analgesic, oral rehydration, antacid, anxiolytic, appetizer, cough syrup, erectile dysfunction, haematinic, hand sanitizer, health supplement, insecticide, laryngitis, pharyngitis, laxative, lubricant, mosquito repellant, nasal decongestant, nutritional supplement, moisturizer, prickly heat powder, skin lightening lotion, vaginal contraceptive, vaginal hygiene, and vitamin supplements, as well as medicated, complexion, moisturizing, and total protection soaps. The company also exports its products. Bliss GVS Pharma Limited was incorporated in 1984 and is based in Mumbai, India.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。